Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
The equity incentive compensation plan amendments received 10,906,889 votes in favor and 584,632 against.
Rhea-AI Summary
Medexus Pharmaceuticals (MEDXF) elected all seven director nominees at its September 24, 2026 virtual annual meeting of shareholders.
The directors will serve through the next annual meeting. Votes in favor ranged from 79.163% for Benoit Gravel to 99.435% for Stephen Nelson. Shareholders approved the appointment of PricewaterhouseCoopers as auditor with 99.560% voting for it. They also approved amendments to the equity incentive compensation plan with 94.912% voting for them. A report of all meeting votes will be filed with Canadian securities regulators.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 24, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders elected all nominees listed in Medexus's management information circular dated August 10, 2026 as directors through the next annual meeting. Shareholders also voted in favor of the appointment of PricewaterhouseCoopers LLP as the company's auditors and in favor of resolutions amending the company's equity incentive compensation plan.
Detailed voting results for the election of directors are set out in the table below.
| Name | For | Against |
| Ken d'Entremont | ||
| Harmony Garges | ||
| Benoit Gravel | ||
| Michael Mueller | ||
| Stephen Nelson | ||
| Nancy Phelan | ||
| Menassie Taddese |
Shareholders also cast 13,812,075 (
A report of the voting results on all matters voted on at the annual meeting will be filed with Canadian securities regulatory authorities at www.sedarplus.ca.
About Medexus
Medexus is a leading pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on hematology and hemato-oncology products, including cell and gene therapy products, and historically also on rheumatology and allergy products. For more information about Medexus and its product portfolio, please see the company's corporate website at www.medexus.com and its filings on SEDAR+ at www.sedarplus.ca.
Contacts
Ken d'Entremont | CEO, Medexus Pharmaceuticals
Tel: 905-676-0003 | Email: ken.dentremont@medexus.com
Brendon Buschman | CFO, Medexus Pharmaceuticals
Tel: 416-577-6216 | Email: brendon.buschman@medexus.com
Victoria Rutherford | Adelaide Capital
Tel: 480-625-5772 | Email: victoria@adcap.ca
Forward-looking statements
Certain statements in this news release contain forward-looking information within the meaning of applicable securities laws, also known and/or referred to as "forward-looking information" or "forward-looking statements". The words "believes", "expects", "will", and similar words, phrases, or expressions are often intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words, phrases, or expressions. Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. Actual results could differ, and could differ materially, from the expectations contemplated by the forward-looking statements. Material risk factors include, but are not limited to, those set out in Medexus's materials filed with the Canadian securities regulatory authorities from time to time, including Medexus's most recent annual information form and management's discussion and analysis. Accordingly, undue reliance should not be placed on these forward-looking statements, which are made only as of the date of this news release. Other than as specifically required by law, Medexus undertakes no obligation to update any forward-looking statements to reflect new information, subsequent or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/315965
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Which Medexus (MEDXF) director nominees received the most and least support?
Stephen Nelson received the most support, with 11,426,618 votes for (99.435%). Benoit Gravel received the least, with 9,097,024 votes for (79.163%). Both were elected.